Alfredo Zurlo
Plus aucun poste en cours
Profil
Alfredo Zurlo served as Co-Managing Director at Glycotope GmbH.
He then worked as Chief Medical Officer at MOLOGEN AG from 2013 to 2016.
After that, he served as Chief Medical Officer at Scandion Oncology A.
Zurlo holds a doctorate degree from The American University of Rome.
Anciens postes connus de Alfredo Zurlo
| Sociétés | Poste | Fin |
|---|---|---|
| MOLOGEN AG | Directeur Technique/Scientifique/R&D | 31/03/2016 |
| SCANDION ONCOLOGY A/S | Directeur Technique/Scientifique/R&D | - |
Glycotope GmbH
 Glycotope GmbH BiotechnologyHealth Technology Glycotope GmbH operates as a biotechnology company to develop pharmaceutical therapeutics and nutrition additives. It focuses on the optimization and humanization of therapeutically relevant sugar structures on biopharmaceuticals known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. The company was founded by Steffen Goletz and Andreas Eckert in Febraury 2001 and is headquartered in Berlin, Germany. | Directeur Général | - |
Formation de Alfredo Zurlo
| The American University of Rome | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MOLOGEN AG | Commercial Services |
| SCANDION ONCOLOGY A/S | Health Technology |
| Entreprise privées | 1 |
|---|---|
Glycotope GmbH
Glycotope GmbH BiotechnologyHealth Technology Glycotope GmbH operates as a biotechnology company to develop pharmaceutical therapeutics and nutrition additives. It focuses on the optimization and humanization of therapeutically relevant sugar structures on biopharmaceuticals known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. The company was founded by Steffen Goletz and Andreas Eckert in Febraury 2001 and is headquartered in Berlin, Germany. | Health Technology |